The Federal Government has announced the listing of ravulizumab (Ultomiris®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of adults with neuromyelitis optica spectrum disorders (NMOSD). This is a…
MS Australia is very pleased to see that health is the number one issue in this election, with solid commitments to reduce the costs of medicine and improve access to…
On International Women’s Day, we look at the disproportionate effects MS has on Australian women and the research MS Australia is supporting to address it….
A new multiple sclerosis (MS) research project designed to help the brain repair itself by activating its own healing processes has been announced as part of MS Australia’s latest $5.7…
MS Australia is inviting Australians with MS, their friends, family, carers, doctors, MS staff, nurses, researchers, and the broader MS community to join in the discussion to share which areas…
As we barrel towards another election, CEO Rohan Greenland urges politicians to back MS Australia’s three priorities to improve the lives of people living with MS and pave the way…
Launching in mid-2025, the new Australian MS app InforMS is designed to help people manage their MS, creating a “one-stop shop” to hold their health information. People living with MS…
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider ublituximab (Briumvi®) for treating relapsing remitting MS at their May 2025 meeting….
Bunbury local Lynda Whitton, a dedicated champion for people living with multiple sclerosis (MS), has been awarded MS Australia’s highest honour, the 2024 John Studdy Award….
